Merrimack Names CFO
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals, Inc. has named Dr Yasir Al-Wakeel chief financial officer and head of corporate development – effective from Aug. 11, 2015. Al-Wakeel will serve a key role in continuing to build Merrimack into a fully integrated cancer company based on a systems engineering approach, the company noted. Merrimack currently has a pipeline of oncology candidates led by MM-398 (irinotecan liposome injection), which is currently under FDA review for approval in post-gemcitabine metastatic pancreatic cancer. Prior to joining Merrimack, Al-Wakeel was a director on the healthcare investment banking team at Credit Suisse.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.